228 related articles for article (PubMed ID: 32338754)
21. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
22. Medicare Part D coverage gap and diabetes beneficiaries.
Schmittdiel JA; Ettner SL; Fung V; Huang J; Turk N; Quiter ES; Swain BE; Hsu JT; Mangione CM
Am J Manag Care; 2009 Mar; 15(3):189-93. PubMed ID: 19298100
[TBL] [Abstract][Full Text] [Related]
23. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
24. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
25. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
McWilliams JM; Zaslavsky AM; Huskamp HA
JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
[TBL] [Abstract][Full Text] [Related]
26. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
[TBL] [Abstract][Full Text] [Related]
28. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
29. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
[TBL] [Abstract][Full Text] [Related]
30. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
31. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
32. Part D coverage gap reform: trends in drug use and expenditures.
Park J; Look KA
Am J Manag Care; 2020 Aug; 26(8):349-356. PubMed ID: 32835462
[TBL] [Abstract][Full Text] [Related]
33. Medicare part D after 2 years.
Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
[TBL] [Abstract][Full Text] [Related]
34. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
35. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
36. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
37. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
38. Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries.
Joyce G; Henkhaus LE; Gascue L; Zissimopoulos J
Health Aff (Millwood); 2018 Oct; 37(10):1578-1586. PubMed ID: 30273018
[TBL] [Abstract][Full Text] [Related]
39. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
[TBL] [Abstract][Full Text] [Related]
40. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]